Abstract
<h3>Purpose/Objective(s)</h3> Stereotactic body radiotherapy (SBRT) is an important treatment option for liver metastases in those who may be unsuitable for surgery and has been shown to have favorable local control and overall survival. This was a single-institution study that characterized the outcomes of 88 patients and 99 lesions treated with SBRT. <h3>Materials/Methods</h3> We retrospectively reviewed outcomes of 88 patients with liver metastasis who were treated with SBRT between August 2010 and August 2019. All data was entered into data collection web application, a secure computer program, and was then exported with de-identified patient information for statistical analysis. Variables of interest included demographic characteristics, primary histology, and local / distant recurrence. The method of Kaplan-Meier was used to characterize overall survival, progression-free survival and time to local/regional recurrence. Cox proportional hazards models were used to evaluate the associations between time-to-event endpoints and demographic characteristics. <h3>Results</h3> Among 88 patients with 99 lesions, 26% were metastatic from colon, 11% from pancreas, 11% from lung, 8% from rectum, and 44% other. Median GTV was 25.8cc with a median dose of 50Gy of radiation prescribed and a mean liver dose of 10.5Gy. Twenty-five (28%) of patients received other liver-directed therapies such as cryoablation, surgical resection, transarterial chemoembolization, microwave ablation, radiofrequency ablation. On univariate analysis, those with a worse performance status had worse survival (performance status 2/3: HR 2.63, p=0.01). On Kaplan-Meier analysis, median overall survival was 25.6 months and median progression-free survival was 7.0 months. On proportional hazards models, median time to local or regional recurrence was 15.4 months. <h3>Conclusion</h3> Liver SBRT resulted in a longer time to local or regional recurrence for oligometastatic disease. Overall survival and progression free survival were acceptable and consistent with historical controls. More favorable overall survival was associated with those who had a better performance status at baseline.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
